Conclusions
The findings of this study suggest to consider 62 putative severe DDI pairs of LPV/RTV identified from two international evidenced-based drug interactions resources predicted to cause clinically significant life-threatening ADRs in COVID-19 patients. It is also suggested that systematic cross-comparisons may help to identify discrepancies in between the drug interaction resources. Further, it is highly suggested that clinicians should not entirely rely on any individual DDI resource for checking life threatening ADRs of LPV/RTV in patients with COVID-19 since there were disagreements in enlisting contraindicated drugs.
Conflict of interest: No conflict of interest.
Funding: No funding was available.
Data availability: All data used in this analysis are available upon request.